StudyFinder
NRG-GU012: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
Status: Recruiting
The primary purpose of this study is to find out if adding a highly focused form of radiation therapy (called SABR) to the main kidney tumor, along with immunotherapy, helps people with advanced kidney cancer live longer or do better than using immunotherapy by itself.
Sex: Male or Female
Age Group: 18 years and over
Inclusion Criteria:
• diagnosis of renal cell cancer with positive lymph nodes that can't be removed or metastasis to another area
• not recommended for or refused immediate nephrectomy
• must agree to use a highly effective contraception while on study drug and for 6 months following the last dose of study drug
• see link to clinicaltrials.gov for complete inclusion criteria
Exclusion Criteria:
• untreated or unstable brain metastases
• prior radiotherapy to the kidney
• systemic therapy for metastatic renal cell carcinoma (RCC) that was initiated > 90 days before starting the study
• women who are pregnant or breastfeeding -see link to clinicaltrials.gov for complete exclusion criteria
Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC), Kidney Cancer, Metastatic Renal Cell Carcinoma
Study Contact: Ian Okazaki - okaza001@umn.edu
Principal Investigator: Ian Okazaki
Phase: PHASE2
IRB Number: STUDY00025313
See this study on ClinicalTrials.gov